Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure

Abstract

Spironolactone improves atrial conduction and remodeling in patients with HF.

Effects of Add-on Therapy Consisting of a Selective Mineralocorticoid Receptor Blocker on Arterial Stiffness in Patients with Uncontrolled Hypertension

“…This effect is similar to previous findings (24)(25)(26). Although the current patients did not clinically present with symptoms of overt heart failure, the present findings suggest that eplerenone may help to prevent the future progression of heart failure in such patients.…”

Impact of Mineralocorticoid Receptor Antagonists on Changes in Cardiac Structure and Function of Left Ventricular Dysfunction

“…The primary search for clinical trials on MRAs and left ventricular dysfunction generated 559 potentially relevant articles, of which 19 met the selection criteria and were published between 1995 and 2011. [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] A flow diagram schematized the process of selecting and excluding articles with specific reasons (Figure 1). Five of 19 qualified trials recorded outcomes within >1 time point in treatment, yielding a total of 26 studies conducted exclusively in subgroup analyses by treatment durations.…”

Eplerenone might affect atrial fibrosis in patients with hypertension

“…Data are presented as mean ± standard deviation (SD). The sample size calculations were based on the previous studies about the effect of mineralocorticoid receptor antagonists and calcium channel blockers, which reported that the percent change in Ad after the administration of spironolactone and calcium channel blockers was 6% and 0%, respectively . Based on these data, assuming the SD of percent change in Ad of 6%, it was estimated that inclusion of 17 patients in each group allowed for a statistical power of 80% and a type I error rate of 0.05.…”